{"name": "Incyte",
 "permalink": "incyte",
 "crunchbase_url": "http://www.crunchbase.com/company/incyte",
 "homepage_url": "http://www.incyte.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "302-498-6700",
 "description": "",
 "created_at": "Wed Jan 13 10:08:05 UTC 2010",
 "updated_at": "Sat Aug 06 19:14:53 UTC 2011",
 "overview": "\u003Cp\u003EIncyte is a drug discovery and development company which hopes to build a proprietary product pipeline of novel small molecule drugs. Incyte\u0026#8217;s product pipeline is currently focused on oncology and inflammation and includes compounds in various stages of development. Through partnerships with \u003Ca href=\"/company/novartis\" title=\"Novartis\" rel=\"nofollow\"\u003ENovartis\u003C/a\u003E, \u003Ca href=\"/company/eli-lilly\" title=\"Eli Lilly\" rel=\"nofollow\"\u003EEli Lilly\u003C/a\u003E, and \u003Ca href=\"/company/pfizer\" title=\"Pfizer\" rel=\"nofollow\"\u003EPfizer\u003C/a\u003E, Incyte intends to promote the clinical development and global commercialization of several of their compounds.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[107,
       79],
      "assets/images/resized/0007/3158/73158v2-max-150x150.png"],
     [[107,
       79],
      "assets/images/resized/0007/3158/73158v2-max-250x250.png"],
     [[107,
       79],
      "assets/images/resized/0007/3158/73158v2-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": true,
    "title": "Chairman",
    "person":
     {"first_name": "Richard",
      "last_name": "DeSchutter",
      "permalink": "richard-deschutter",
      "image": null}},
   {"is_past": true,
    "title": "Senior Vice President",
    "person":
     {"first_name": "James",
      "last_name": "D. Watson",
      "permalink": "james-d-watson",
      "image": null}},
   {"is_past": true,
    "title": "Director of Investor Relations \u0026 Corp Com",
    "person":
     {"first_name": "Paul",
      "last_name": "Chirico",
      "permalink": "paul-chirico",
      "image":
       {"available_sizes":
         [[[147,
            150],
           "assets/images/resized/0025/4940/254940v1-max-150x150.jpg"],
          [[150,
            153],
           "assets/images/resized/0025/4940/254940v1-max-250x250.jpg"],
          [[150,
            153],
           "assets/images/resized/0025/4940/254940v1-max-450x450.jpg"]],
        "attribution": ""}}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "Experimental Station",
    "address2": "Route 141 \u0026 Henry Clay Road, Building E336",
    "zip_code": "19880",
    "city": "Wilmington",
    "state_code": "DE",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Incyte earns $19M milestone from Lilly",
    "stoned_year": 2010,
    "stoned_month": 10,
    "stoned_day": 20,
    "source_url": "http://www.fiercebiotech.com/story/incyte-earns-19m-milestone-lilly/2010-10-20?utm_medium=rss\u0026utm_source=rss",
    "source_text": "",
    "source_description": "Incyte earns $19M milestone from Lilly",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Incyte",
      "permalink": "incyte"}},
   {"description": "Incyte announces $775 million collaboration with Eli Lilly",
    "stoned_year": 2009,
    "stoned_month": 12,
    "stoned_day": 21,
    "source_url": "http://newsroom.lilly.com/releasedetail.cfm?ReleaseID=431576",
    "source_text": "",
    "source_description": "Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Incyte",
      "permalink": "incyte"}},
   {"description": "Incyte lands $50M milestone from Novartis",
    "stoned_year": 2010,
    "stoned_month": 11,
    "stoned_day": 2,
    "source_url": "http://www.fiercebiotech.com/story/incyte-lands-50m-milestone-novartis/2010-11-02",
    "source_text": "",
    "source_description": "Incyte lands $50M milestone from Novartis",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Incyte",
      "permalink": "incyte"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        110],
       "assets/images/resized/0007/3159/73159v1-max-150x150.jpg"],
      [[250,
        184],
       "assets/images/resized/0007/3159/73159v1-max-250x250.jpg"],
      [[450,
        332],
       "assets/images/resized/0007/3159/73159v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}